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European Blood and Marrow Transplantation Registry (EBMT)Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patients with
relapsed diffuse large B cell lymphoma. The impact of rituximab combined with chemotherapy in either first-
or second-line therapy on the ultimate results of ASCTremains to be determined, however. This study was
designed to evaluate the benefit of ASCT in patients achieving a second complete remission after salvage che-
motherapy by retrospectively comparing the disease-free survival (DFS) after ASCT for each patient with the
duration of the first complete remission (CR1). Between 1990 and 2005, a total of 470 patients who had un-
dergone ASCTand reported to the European Blood and Bone Transplantation Registry withMedical Essential
Data FormB information were evaluated. Of these 470 patients, 351 (74%) had not received rituximab before
ASCT, and 119 (25%) had received rituximab before ASCT. The median duration of CR1 was 11 months. The
median time from diagnosis to ASCTwas 24 months. The BEAM protocol was the most frequently used con-
ditioning regimen (67%). After ASCT, the 5-year overall survival was 63% (95% confidence interval, 58%-67%)
and 5-year DFS was 48% (95% confidence interval, 43%-53%) for the entire patient population. Statistical
analysis showed a significant increase in DFS after ASCT compared with duration of CR1 (median, 51 months
versus 11 months; P\ .001). This difference was also highly significant for patients with previous exposure
to rituximab (median, 10 months versus not reached; P \ .001) and for patients who had experienced
relapse before 1 year (median, 6 months versus 47 months; P \ .001). Our data indicate that ASCT can
significantly increase DFS compared with the duration of CR1 in relapsed diffuse large B cell lymphoma
and can alter the disease course even in patients with high-risk disease previously treated with rituximab.
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During the last decade, the addition of the anti-
CD20 monoclonal antibody rituximab to various
chemotherapies has dramatically improved overall sur-
vival (OS), progression-free survival (PFS), and
response rates in patients with diffuse large B cell lym-
phoma (DLBCL), with complete responses ranging
from 75% to 80% [1]. However, despite this major ad-
vance in first-line treatment, a significant proportion
of patients experience relapse after the initial chemo-
therapy, especially patients with high-risk scores on
the International Prognostic Index (IPI) [2,3].
Before the advent of rituximab, the standard thera-
peutic approach for relapsed DLBCL was to decrease
the tumor burden and assess chemosensitivity with
a second-line therapy, and then consolidate the remis-
sion status with high-dose therapy and autologous
stem cell transplantation (ASCT). Using this approach,
the 5-year OS was 53% [4]. The sole prospective ran-
domized trial of patients with DLBCL in first relapse
or primary refractory to first-line therapy in the rituxi-
mab era was the CORAL trial, which included 396 pa-
tients [5]. The patients were randomized between 2
widely used regimens, ICE (ifosfamide, carboplatin,
etoposide) and DHAP (dexamethasone, high-dose
ara-c, cisplatinum), both of which were combined
with rituximab (R-ICE and R-DHAP). No difference
in outcome between the R-ICE and R-DHAP groups
was seen. However, various parameters greatly affected
the results of ASCT, including chemotherapy sensitiv-
ity before ASCT, previous treatment with rituximab,
and time fromdiagnosis to relapseof\12months.Nev-
ertheless, to date no comparative study has evaluated
the efficacy of ASCT according to these subgroups.
Moreover, the outcome of relapsed patients without
ASCTispoor,with\10%ofpatients alive at 5 years [1].
The purpose of the present study was to evaluate the
efficacy of ASCT in the rituximab era by retrospectively
comparing thedurationof disease-free survival (DFS) af-
ter ASCTwith the duration of the last disease phase just
before the phase that included ASCT in each patient
studied. Only chemosensitive patients in complete re-
mission (CR) before ASCT were eligible for the study,
becausethesepatients arethebest candidates fora salvage
strategy. The aim of this approach, which has been used
to develop new drugs such as I-131 tositumomab [6] and
to evaluate ASCT in indolent non-Hodgkin lymphoma
[7], was to ascertain whether ASCT lengthens the
disease-free period during the disease course and ulti-
mately has the potential to cure the disease.
PATIENTS AND METHODS
Study Design
The European Blood and Marrow Transplanta-
tion registry (EBMT) is a voluntary organizationcomprising 525 transplantation centers located mainly
in Europe. Member centers are required to submit
minimal essential data (MED-A form; www.ebmt.org)
from consecutive patients to a central lymphoma
registry in which patients are identified by subtype of
lymphoma and type of transplantation. Participating
transplantation centers are subject to onsite audits to
assess data accuracy and consecutive reporting.
Informed consent was obtained locally according to
regulations applicable at the time of transplantation.
Since January 1, 2003, all EBMT centers have been
required to obtain written informed consent before
data registration according to the Declaration of
Helsinki of 1975.
This study was designed to evaluate the benefit of
this strategy in patients with DLBCL who achieved
secondCR (CR2) after salvage chemotherapy by retro-
spectively comparing the DFS after ASCT with the
duration of the first CR (CR1) for each patient. Partial
responders, stable patients, and patients with progres-
sive disease were excluded. The EBMT database was
used to identify adult patients with DLBCL treated
with a first ASCT in CR2 between 1990 and 2005.
The registry included a total of 1166 such patients,
only 470 of whom had a fully documented ASCT
with an EBMT MED-B form. To avoid any bias
related to the analysis of the patients with a MED-B
form, both populations were compared in terms of
4 major outcomes: nonrelapse mortality (NRM),
relapse rate (RR), DFS, and OS. No significant differ-
ences between the 2 populations were seen, and the
470 patients with fully documented ASCT informa-
tion were used in further studies.
Patient and Transplant Characteristics
Characteristics of the patients and transplants are
summarized in Table 1. The median patient age was
52 years (range, 18-74 years). Of the 470 patients,
275 (59%) underwent ASCT before 2002, and 351
(74%) did not receive rituximab before undergoing
ASCT. Among the remaining 119 patients (25%)
who did receive rituximab, 114 were treated between
2002 and 2005, 15 received rituximab during first-
line treatment, 26 received rituximab in the relapse set-
ting, and 41 received rituximab both during first-line
treatment and after relapse. Information was not avail-
able for 32 patients. The median time from diagnosis
to ASCT was 24 months (range, 6-395 months). The
median duration of CR1 was 11 months (range,
1-112 months), and CR1 lasted\12 months in 49%
of cases.
Statistical Methods
DFS was measured from the date of ASCT to the
date of disease relapse or death. OS was measured
from the date of ASCT to the date of death from any
cause. DFS and OS curves were generated using the
Figure 1. Disease course of relapsed patients with DLBCL. Each pa-
tient is considered his or her own control.
Table 1. Characteristics of Patients at ASCT
Characteristic n (%)
5-Year
OS, %
P
Value
5-Year
DFS, %
P
Value
Sex
Male 262 (56) 62 47
Female 208 (44) 63 .80 46 .90
Age
<50 years 209 (45) 69 54
$50 years 261 (55) 56 .002 39 .003
Relapse before ASCT
<12 months 240 (51) 61 47
$12 months 230 (49) 62 .30 44 .50
Previous rituximab therapy
Yes 119 (25) 74 60
No 351 (75) 63 .10 49 .05
Number of chemotherapy regimens
2 412 (88) 62 47
3 37 (8) 57 42
4 8 (2) 53 38
5 or 6 13 (3) 53 .20 38 .40
Conditioning regimen
TBI/VP16/cyclophosphamide 20 (4) 52 40
BEAM 314 (66) 60 44
CBV 10 (2) 59 48
BuCy 4 (1) 70 50
Other protocol 132 (27) 52 .40 40 .70
Stem cell source
Bone marrow 60 (13) 60 44
Peripheral blood 399 (85) 63 46
Both 11 (2) 62 .70 45 .80
BEAM indicates BCNU, VP16, cytarabine, and cyclophosphamide; BuCy,
busulfan and cyclophosphamide; CBV, cyclophosphamide, BCNU, and
VP16; TBI, total body irradiation.
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mined using cumulative incidents to account for com-
peting risks. The primary endpoint of the study was
DFS after ASCT, and the log-rank test was used to
compare groups. The study’s main objective was to
evaluate the benefit of ASCT in CR2 by comparing
DFS with the duration of CR1, using each patient as
his or her own control. This approach is illustrated
in Figure 1.
The duration of DFS and duration of CR1 were
compared using the paired Wilcoxon signed rank test
in the entire series and in defined subsets of patients. If
a patient had not relapsed by the time of follow-up and
if the duration of follow-up after ASCT was longer
than the duration of CR1, then the impact of ASCT on
DFS was considered positive for that patient. Some
patients could not be included in the paired test
because they had been censored because of having
a shorter durationof follow-up than thedurationofCR1.
All statistical analyses were performed using the
SPSS 15.0 statistical package (SPSS, Inc., Chicago,
IL) andNCSS97 software (Number Cruncher Statisti-
cal System, Kaysville, UT). A P value\.05 was consid-
ered significant.
RESULTS
Patient and transplant characteristics are summa-
rized in Table 1. All of the patients were in CR2 after
salvage chemotherapy before ASCT, and 88% of themreceived 2 regimens. The BEAM conditioning regi-
men was used in 67% of patients, with peripheral
stem cell support in 85% of cases. At diagnosis, age-
adjusted IPI (aaIPI) was available in 141 patients;
values were 0-1 in 40% of the patients and 2-3 in
60%; bulky disease was present in 13%. At relapse,
the aaIPI was 0-1 in 63% and 2-3 in 37%.
Survival
The median follow-up time after ASCT for the
305 surviving patients was 52 months. A total of 196
cases (42%) relapsed after ASCT, at a median of
10 months (range, 1-172 months). The 5-year cumula-
tive incidence of relapse was 45% (95% confidence
interval [CI], 40%-50%) (Figure 2A). Thirty-five pa-
tients (7%) experienced NRM (cumulative incidence
of 6% at 3 years; 95%CI, 4%-9%) (Figure 2A). A total
of 239 patients (51%) were alive and disease-free after
ASCT at the time of follow-up. The estimated 5-year
DFS and OS were 48% (95%CI, 43%-53%) and 63%
(95% CI, 58%-67%), respectively (Figure 2B).
The association between the main patient charac-
teristics and DFS calculated by univariate analysis
showed that age at ASCT (#50 years versus.50 years)
was a significant prognostic factor (3-year DFS, 60%
versus 48%; P 5 .004). The DFS curves according to
CR1 duration showed nonproportional hazards over
time. In this regard, the impact of this variable was
investigated by separating the posttransplantation
course into several different periods. A short duration
of CR1 (\12 months versus $12 months) was associ-
ated with a worseDFS in the initial period after ASCT,
with a DFS of 52% versus 67% at 2 years (P 5 .003)
and no differences at longer follow-up periods. Finally,
previous treatment with rituximab was associated with
a better DFS after ASCT, with borderline significance
(DFS at 3 years, 68% versus 55%; P5 .05). This factor
was investigated in patients who underwent ASCT
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Figure 2. Overall outcome of the entire series (n5 470). (A) Relapse
rate and nonrelapse mortality. (B) DFS and OS.
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Figure 3. Duration of first complete remission and DFS after the
ASCT for the entire series (n 5 470).
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ferences between the 81 patients who underwent
ASCT after 2002 and never received rituximab versus
the 270 patients who never received rituximab (TRM,
4% versus 3%; male sex, 56% versus 54%; IPI 2-3,
66% versus 67%; age .50 years, 45% versus 44%;
DFS at 5 years, 43% versus 41%).
In summary, in patients with DLBCL, duration of
CR1, previous treatment with rituximab, and age at
ASCT were identified as prognostic factors for DFS
after ASCT in CR2.Comparative Survival Analysis by Patient
We then compared DFS duration and CR1 dura-
tion using each patient as his or her own control.
The duration of CR1 and DFS after ASCT are shown
in Figure 3. When each patient was assessed as his or
her own control, the statistical analysis showed a signif-
icant increase in the duration of DFS after ASCT
(P\ .001). Fifty-eight patients could not be included
in the paired analyses because of insufficient follow-up.
In the remaining 412 patients, the duration of DFS af-
ter ASCT was longer than the duration of previousCR1 for 291 patients (71%) and shorter for 121 pa-
tients (29%).
To better evaluate the benefit of ASCT consolida-
tion for each patient, we analyzed several subgroups of
patients. Follow-up duration was sufficient for inclu-
sion in paired analysis in 228 patients with a CR1
shorter than 12 months and 184 patients with a CR1
longer than 12 months. The duration of DFS after
ASCT was longer than the duration of previous CR1
in 80% of the patients in the first group (P\ .001)
and in 58% of the patients in the second group (P 5
.002). The duration of DFS exceeded that of previous
CR1 in 66% of the 313 patients not previously treated
with rituximab (P \ .001), compared with 88% of
the 99 patients previously treated with rituximab
(P\ .001). We also looked for potential differences
between the groups ‘‘CR2 shorter than CR1’’ and
‘‘CR2 longer than CR1,’’ considering clinical charac-
teristics and rituximab administration. The only differ-
ence between these 2 groups was in the rate of previous
rituximab treatment (15% versus 27%; P 5 .001),
which persisted in the 2 subsets: CR1 duration \1
year (16% versus 31%; P 5 .04) and CR1 duration
.1 year (14% versus 21%; P 5 .20).
To examine the effect of age at ASCT, 192 patients
age\50 years and 220 patients age$50 years were in-
cluded in the paired analyses. These analyses showed
that ASCT significantly increased DFS after CR2 in
both subgroups compared with the duration of CR1
(74% and 66% of the cases, respectively; P \ .001
for both groups).DISCUSSION
In response to the dramatic improvement in the
treatment of DLBCL with rituximab therapy, several
questions have been raised regarding the role of con-
solidation with ASCT in relapsed patients and whether
the introduction of rituximab has changed the situa-
tion. The role and the quality of salvage chemotherapy
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Figure 4. Impact of rituximab administration before ASCTon DFS in
patients who underwent autografting between 2002 and 2005.
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addition of rituximab to second-line chemotherapy
followed by ASCT has significantly improved PFS in
patients not exposed to rituximab as part of their
first-line treatment [8]. However, previous exposure
to rituximab during first-line treatment was an adverse
prognostic factor for response to salvage treatment
with rituximab in the CORAL trial [5], with only
one-half of the patients responding.
Given the infeasibility of conducting a randomized
study comparing salvage chemoimmunotherapy fol-
lowed by ASCTwith no ASCT, we decided to examine
the outcomes of patients who had undergone ASCT
while in first relapse and to compare the duration of
the CR before ASCT with the duration of CR after
ASCT in each patient. To avoid investigator bias in
the definition of partial responders, only patients in
CR2 or with a MED-B form available were included.
Before the rituximab era, the 5-year OS for
relapsed DLBCL was 53% after high-dose chemo-
therapy and ASCT [4]. In the present study, our entire
series of 470 patients had a projected 5-year OS of
63%. This 10% improvement since the 1980s might
be attributed to better supportive care measures during
the immediate post-ASCT period and the use of ritux-
imab combined with salvage chemotherapy. The
CORAL trial’s 3-year OS of 68% for 206 patients
who underwent ASCT [5] was similar to our finding.
For those patients who achieve CR before ASCT,
a clear benefit is seen in the reduction of RR compared
with elderly patients not consolidated with an ASCT.
No data are available for relapsed patients age
\65 years treated with chemotherapy only. In one
study, elderly patients who experienced disease pro-
gression after R-CHOP chemotherapy had a median
OS of 0.6 year and a 3-year survival rate of 18% [1].
Nevertheless, several factors adversely affect outcome
after ASCT, including age .50 years and CR1duration of\12 months. However, the positive effect
of previous rituximab exposure may reflect the quality
of response before ASCT in all of these responding
patients (Figure 4). In addition, this impact was seen
mostly in patients treated with rituximab after relapse,
and was not seen in patients treated up front and at
relapse with rituximab chemotherapy or in patients
who never received rituximab (data not shown). The
underlying biology of the disease cannot be ascer-
tained from clinical parameters alone; genomic pro-
files are needed as well [9]. Consequently, the finding
that a patient who had experienced one relapse did
not relapse again after salvage chemotherapy and
ASCT implies that the new treatment is efficient.
Similarly, an increase in the disease-free duration after
ASCT can lead to the same conclusion.
In the present study, when each patient was as-
sessed as his or her own control, the duration of PFS
after ASCT exceeded that of CR1, demonstrating
that ASCT can alter the course of disease. This differ-
ence in favor of the post-ASCT period was significant
in patients with previous exposure to rituximab and
relapse before 1 year. Overall, the 5-year DFS of
48% suggests that ASCT can change the disease
course even in high-risk relapsed DLBCL patients.
These results can be extrapolated to relapsed patients
who achieve partial response after salvage chemother-
apy, as shown in the CORAL trial. Our results must be
viewed with caution, however, given the retrospective
nature of our analysis, the inclusion of some inherent
selection bias, and the fact that the quality of tumor
response was not investigated in more detail by posi-
tron emission tomography using [18F]-fluoro-2-
deoxy-D-glucose [10].
In conclusion, the quality of salvage chemotherapy
must be improved, and the most appropriate treatment
should be identified by considering the characteristics
of those patients who experience relapse after chemo-
immunotherapy. Because approaches to predicting
outcome after treatment using microarray genome-
wide techniques are still not available in the clinical
setting, ASCT remains a good therapeutic option for
patients with chemosensitive relapsed DLBCL. Spe-
cific efforts aimed at identifying those patients with
refractory disease at early stages are crucial. In this
context, new approaches, including allogeneic trans-
plantation [11,12] and novel targeted therapies
developed as a result of a better understanding of the
biology of the disease [13], will play key roles.ACKNOWLEDGMENTS
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